Search results
These Inhalers No Longer Cost More Than $35 Per Month
Verywell Health via Yahoo News· 1 month agoGrace Cary / Getty Images Fact checked by Nick Blackmer Key Takeaways Three major pharmaceutical...
GSK Gears Up for Q1 Earnings: Here's What to Expect
Zacks via Yahoo Finance· 1 day agoWe expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
Innoviva Inc (INVA) Reports Growth Amidst Challenges in Q4 and Full Year 2023 Financial Results
GuruFocus.com via Yahoo Finance· 2 months agoRevenue: Innoviva Inc (NASDAQ:INVA) reported a 35% year-over-year increase in net product revenues...
GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US
Zacks via Yahoo Finance· 1 month agoGSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month...
Theravance Biopharma (TBPH) to Sell Trelegy Royalty Interests
Zacks via Yahoo Finance· 2 years agoTheravance Biopharma (TBPH) agrees to sell its Trelegy royalty interests to Royalty Pharma. The...